Saturday 17 October 2026
Export NMAD’s income statement to Excel — free account
Nomad Power Solutions, Inc.
NMAD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 44.8% and free cash flow fell 230.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
3.88
0.21
−5.13%
Follow NMAD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.88 | 3.60 | 13.73 | 14.05 | 16.82 | 24.15 | 11.23 | 20.55 | 3.67 | 1.98 |
Net Debt/EBITDA |
1.00 | 0.29 | 0.83 | 0.85 | 0.72 | 1.55 | 1.04 | 2.00 | 0.72 | 0.09 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.51 | 0.88 | 0.84 | 0.73 | 0.62 | 0.65 | 0.69 | 0.71 | 0.78 | 0.79 |
Capex/Depreciation |
0.00 | — | — | — | — | — | — | — | — | — |
Interest Coverage |
(555.17) | (212.67) | (314.21) | (709.16) | (908.16) | (882.81) | (50.10) | (872.69) | (2,585.43) | (21,349.00) |
| (185.40%) | 329.29% | (471.02%) | (427.17%) | (480.21%) | (1,463.75%) | 1,108.98% | 227.02% | 62.46% | 73.73% | |
| (87.59%) | (131.50%) | (103.08%) | (118.50%) | (130.37%) | (82.65%) | (69.64%) | (89.44%) | (834.52%) | (985.09%) | |
ROIC |
(54.52%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(158.08%) | (433.51%) | (127.34%) | (122.21%) | (140.46%) | (65.14%) | (100.25%) | (51.73%) | (181.73%) | (994.27%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | — | — | — | — | — | — |
Free Cash Flow per Share |
(1.18) | (1.41) | (2.24) | (2.92) | (3.07) | (1.89) | (1.50) | (1.54) | (0.15) | (0.21) |
Cash per Share |
1.06 | 0.46 | 2.19 | 3.38 | 3.58 | 4.50 | 2.33 | 4.36 | 0.14 | 0.03 |
Shareholders Equity per Share |
2.26 | 0.37 | 2.09 | 3.27 | 3.56 | 4.44 | 2.18 | 4.21 | 0.11 | 0.03 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.26 | 0.37 | 2.09 | 3.27 | 3.56 | 4.44 | 2.18 | 4.21 | 0.11 | 0.03 |
Free Cash Flow |
(5.71) | (3.16) | (4.29) | (4.61) | (4.14) | (2.13) | (1.67) | (1.51) | (1.41) | (1.68) |
Working Capital |
3.85 | 0.83 | 3.99 | 5.17 | 4.79 | 5.01 | 2.43 | 4.12 | 1.00 | 0.21 |
Capital Expenditures |
(2.64) | — | — | — | — | — | — | — | — | — |
Net Current Asset Value |
3.41 | 0.83 | 3.99 | 5.17 | 4.79 | 5.01 | 2.43 | 4.12 | 1.00 | 0.21 |
| Other line items | ||||||||||
Quick Ratio |
3.83 | 3.26 | 13.39 | 13.53 | 15.93 | 23.41 | 10.98 | 20.26 | 3.50 | 0.91 |
Cash ROIC |
(35.52%) | (169.57%) | (52.37%) | (43.84%) | (43.09%) | (21.14%) | (33.26%) | (17.99%) | (61.38%) | (404.49%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.63) | (1.41) | (2.24) | (2.92) | (3.07) | (1.89) | (1.50) | (1.54) | (0.15) | (0.21) |
Capex per Share |
(0.54) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.26 | 0.12 | 0.19 | 0.23 | 0.21 | 0.17 | 0.17 | 0.25 | 0.25 | — |
Average Assets |
6.94 | 2.73 | 4.93 | 5.33 | 5.16 | 3.95 | 3.50 | 2.39 | 0.22 | 0.22 |
Average Common Equity |
3.28 | (1.09) | 1.08 | 1.48 | 1.40 | 0.22 | (0.22) | (0.94) | (2.90) | (2.90) |
Capex to Sales |
0.00 | — | — | — | — | — | — | — | — | — |
Columns are period end dates